Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking daily life with knee osteoarthritis improve care?

NCT ID NCT06623773

Knowledge-focused Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study follows 136 adults aged 50 to 85 with knee osteoarthritis who are taking the supplement Structum (chondroitin sulfate). Researchers will measure pain, stiffness, and physical function using a standard questionnaire, along with other health factors, at the start and after three months. The goal is to describe the real-world burden of the disease and how it affects quality of life in Poland. Since this is an observational study, it does not test whether Structum works, but rather paints a picture of patients' experiences.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Chondroitin sulfate (Structum), a natural supplement-like drug for osteoarthritis symptoms
What this could lead to
If successful, this study could clarify how much knee osteoarthritis affects daily life and whether current treatment patterns match patients' needs, possibly guiding better care strategies.
What could go wrong
This is an observational study without a control group, so it cannot prove whether Structum works. Results may not apply beyond the Polish population studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

136 people

The number who actually took part.

Started

Jul 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adult patients aged 50 to 85 years with a confirmed diagnosis of knee osteoarthritis and a new prescription for Structum®, as treated by participating centers in Poland.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female patients aged 50 to 85 years at inclusion * of knee OA (either a patient newly diagnosed \[at inclusion\] or with history of knee OA) based on at least the following items 1 and/or 2: 1. knee pain lasting for at least 3 months; 2. patient in the active phase of knee OA disease (knee pain score ≥ 40mm at inclusion on the Visual Analog Scale \[VAS\] 0-100 mm); 3. knee radiographs showing knee joint narrowing and/or osteophytes. * Patients who have been prescribed, for the first time or not, Structum®. * patient taking any non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics should be on stable dose at least one week before inclusion to the study. * Patients able to visit the clinic and attend follow-up visits. * Patients having signed an informed consent form, according to local regulations. Exclusion Criteria: * Patients with any ongoing chondroitin sulfate treatment at inclusion or during the last 3 months. * plasma (in the last 3 months). No glucocorticoids administration in the last 3 months before inclusion. That does not include NSAIDS, paracetamol and other analgesic medications (e.g. tramadol). * Patients with an artificial knee joint, including unilateral. * Patients scheduled to undergo knee replacement surgery in the next 6 months. * Patients with a severe general condition that prevents them from being included in the study as assessed by the investigator. * Patients participating in interventional trials on investigational drugs at the time of inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis,knee are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis,knee

Contacts and locations

Locations

  • Agnieska WIAK

    Lubartów, 21-100, Poland

  • Alina Wołkowicz Mruk

    Krakow, 31-455, Poland

  • Andrzej Majer

    Kujakowice Gorn, 46-211, Poland

  • Bartlomiej Szpyra

    Krakow, 31-155, Poland

  • Elżbieta Pietrus- Dunaszewska

    Katowice, 40-007, Poland

  • Maciej Dołżyński

    Bialystok, 15-481, Poland

  • Marcin Milchert

    Szczecin, 71-497, Poland

  • Mariusz Borowiecki

    Zielona Góra, 65-559, Poland

  • Michał Straburzyński

    Zielona Góra, 65-047, Poland

  • Piotr Ligocki

    Bydgoszcz, 85-091, Poland

  • Sławomir Panek

    Olesno, 46-300, Poland

  • Viktor Kostiuk

    Żagań, 68-100, Poland

  • Wojciech Larczyński

    Nowy Dwór Gdański, 82-100, Poland

  • Wojciech Roczniak

    Ustrzyki Dolne, Ustrzyki Dolne, Poland

  • Zdzisław Derleta

    Warsaw, 03-938, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.